Obesity Is Tied to Hundreds of Gene Variants — Why Are We Only Talking About Two?
Focusing on two gene variants obscures the more complex gene relationships that drive obesity. Here’s what we miss if we only focus on one gene variant at a time.
23andMe Bankruptcy Auction Win Adds Big Piece to Regeneron’s Gene-Based Drug R&D Efforts
Regeneron Pharmaceuticals’ $256 million offer was chosen the winner of 23andMe’s bankruptcy auction. Drug research never became a big part of the genetic testing company’s business, but it is getting a new life by joining Regeneron Genetics Center, a Regeneron subsidiary that analyzes genetic data for drug R&D.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
Beyond Newborn Screening: Four Essential Factors in Congenital Disease Care
These recommendations on how to care for babies who fail newborn screenings offer valuable lessons for public health officials, clinicians, and families.
Anne Wojcicki Had a Fully Financed Plan to Take 23andMe Private. Then It Fell Apart.
A month before 23andMe’s bankruptcy filing, CEO Anne Wojcicki had a fully financed proposal to take the genetic testing company private. The financing fell apart, and a series of alternative proposals by Wojcicki did not result in a deal.
Driving Genetic Testing Adoption and Improved Patient Care through Health Data Intelligence
By fostering collaboration and seamless data integration into healthcare systems, the industry is laying the groundwork for a future in which “personalized medicine” is so commonplace within clinical practice that we will just start calling it “medicine.”
Mass Board Exodus at 23andMe Leaves Company With Tough Decisions Ahead
Months after 23andMe CEO Anne Wojcicki publicly stated she wants to take the company she co-founded private, all of the company’s independent board directors have resigned. The board letter to Wojcicki stated that its members preferred resigning over continuing to have a difference of view over the direction of the company.
presented by
The Healthcare Payments Industry Faces a Perception Challenge
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
9 Requirements for an Optimal Genetic Test Benefit Program
Health plans should be sure the following elements are incorporated into their genetic testing benefits framework.
Navigating the Complexities of Payment for Genetic Testing
Balancing the promise of personalized medicine with proper payment accuracy
Why 1 Health System Is Embedding Genomics Into Primary Care
At Northshore–Edward Elmhurst Health, all patients are offered genetic testing as part of their primary care visit. This helps clinicians create more personalized care plans and facilitates earlier disease diagnoses, said Kristen Murtos, the health system's chief innovation and transformation officer.
Pharmacogenomics Offers New Frontier For Precision Medicine
As the industry moves towards more personalized medicine, pharmacogenomics could play a key role in keeping patients healthier longer and in getting them viable treatments for their unique genetic profile.
presented by
Closing the Quality-Affordability Gap in Workplace Mental Health
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
Nest Genomics Raises $8.5M to Increase Access to Patients’ Genetic Information
Nest Genomics just closed a $8.5 million seed financing round. The company provides the software infrastructure needed for health systems, clinics, drugmakers and payers to launch and scale genomic programs. It also provides tools for patients to easily access their genetic information.
Targeted drug combinations are the next big advance in cancer treatment
Drugs that work for one patient may not work for another, even if both patients have the same diagnosis. This is why each patient should be tested to select the most effective and least toxic drug regimen for that individual before initiating treatment.
As genetic testing expands, evidence and awareness needed to spur adoption
Genetic tests are becoming available for a wider range of applications. During a CB Insights panel discussion, Phil Febbo of Illumina and Alicia Zhou of Color explained what they think needs to happen to make these tests accessible and affordable for more people.
With $60M in new funding, Genome Medical buys genetic counseling company
Telehealth startup Genome Medical recently raised $60 million in funding led by Casdin Capital. It’s using part of the funds to acquire GeneMatters, which would add more genetic counselors to its staff.
NorthShore, Sema4 set up genomics program to advance personalized treatment
The Illinois-based health system is teaming up with the analytics company to launch a genomics program, which will focus on predicting the risk of illness and outcomes among patients. It will also provide free genetic testing to low-income patients in an effort to increase access to genomic care.